Z Squared Inc Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $2.9MTTM through 30 Jun 2026
Net Income -$25.7MTTM through 30 Jun 2026
Free Cash Flow -$8.8MTTM through 30 Jun 2026
Margins
| Current | |
|---|---|
| Gross Margin | -19.8% |
| EBITDA Margin | -831.5% |
| Operating Margin | -910.8% |
| Net Margin | -872.6% |
Returns
-19.4%ROE
-19.1%ROA
Balance Sheet Health
Debt / Equity0.00x
Current Ratio7.66x
Net Debt-$15.3Mnet cash position
Cash & Equivalents$15.5M
Quality Metrics
Altman Z-Score43.12
Piotroski F-Score4 / 9
FCF Margin-298.9%
Multi-Year Trend
RevenueFY2025: $1.4M
Diluted EPS-$3.10TTMFY2025: $-2.81
Dividend
No dividend
Capital Allocation
R&D Spend$1.4M
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| Technology Segment | View detailsThis segment is revenue generating and incurs expenses by acquiring technology assets to support and enhance operational capabilities through advanced technologies. | ||
| Biotechnology Segment | View detailsReflects the historical biopharmaceutical operations, substantially spun out prior to the merger closing on April 24, 2026, except for GEAR Therapeutics, Inc. |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.